Gene expression profiling of sarcoma cells treated with mithramycin A (MTA), nano-encapsulated MTA or MTA-analogs

This study was designed to gain insight about the mechanisms involved in the anti-tumor effects of mithramycin A (MTA) and the MTA analog EC-8042 in sarcoma cells. In addition, we also studied whether this molecular features could be influenced by the nano-encapsulation of MTA. we have performed RNA seq analyses in myxoid liposarcoma T-5H-FC#1 cells treated in triplicate with either DMSO (control), or the IC50 values of free MTA (M_F) (25 nM), MTA loaded in polymeric PLG-nanoparticles (M_NP) (25 nM) or EC-8042 (300 nM) for 24 hours. In addition, this study includes RNA seq analyses of 143B osteosarcoma cells treated with DMSO (control) or the IC50 values of EC-8042 (100 nM) for 24 hours.